VTVT Historical PE Ratio Notes

— vTv Therapeutics (Nasdaq: VTVT) is a clinical-stage pharmaceutical company focused on the discovery and development of orally administered small molecule drug candidates to treat unmet medical needs in diabetes, Alzheimer’s disease, and inflammatory disorders. The company's pipeline is centered around innovative therapies targeting mechanisms such as glucokinase activation for type 2 diabetes and RAGE inhibition for Alzheimer’s and diabetes-related complications. When considering vTv's historical price-to-earnings (PE) ratio, it's crucial to understand that, as a development-stage biotech firm, vTv typically reports little to no revenue and consistent net losses. As a result, their historical PE ratio may be irrelevant or undefined for long periods, which is common among early-stage biotechs. Investors analyzing historical charts and tables will frequently encounter negative or non-applicable PE ratios due to a lack of profitability; this reflects the high-risk, speculative nature of companies like vTv, where valuation tends to be driven not by earnings but by expectations of future clinical success & potential commercialization. Therefore, any apparent historical PE data should be interpreted in the context of milestones in clinical development & news flow, rather than as a traditional measure of value.

On this page we presented the vTv Therapeutics Historical PE Ratio information for vTv Therapeutics' stock. The average VTVT historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 18.2. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average VTVT historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this VTVT historical PE result, against the recent PE: when this page was posted on 5/18/2026, the most recent closing price for VTVT had been 35.49, and the most recent quarterly earnings result, annualized, was 6.6. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent VTVT PE on 5/18/2026 based on annualized quarterly EPS was 5.4. Based on VTVT's history, that recent PE is low relative to the historical average, with the recent PE 70.3% lower than the historical average PE across our data set for vTv Therapeutics.

For self directed investors doing their due diligence on VTVT or any other given stock, valuation analysis for VTVT can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate vTv Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for VTVT. Thanks for visiting, and the next time you need to research VTVT Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.